TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology

Tandem Diabetes Care, Inc. (TNDM) recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is compatible with both the t:slim X2 insulin pump and Tandem Mobi System. It is available for people with type 1 diabetes (ages 2 years and older) and adults with type 2 diabetes.TNDM Stock’s Likely Trend Following the NewsSince the announcement, TNDM’s shares edged up 1.1% at the after-market trading yesterday.Tandem ...